Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition
Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.
You may also be interested in...
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases
BIO is investigating why psychiatric, cardiovascular and some other disease areas draw less deal-making and investment interest. Trillium CEO Niclas Stiernholm talks about the relative lack of VC funding for Canadian biotechs. And Novartis' Jay Bradner shares progress from the company's entrepreneurial NIBR Scholars experiment.